The cost effectiveness of ivabradine in the treatment of chronic heart failure

Source: Heart, 2014, 100 (13) p. 1031-6

Follow this link for fulltext

Date of publication: July 2014

Publication type: Journal article

In a nutshell: This economic evaluation assessed the cost-effectiveness of ivabradine from the perspective of the UK National Health Service, based on the results of the SHIfT trial. Ivabradine is expected to have a 95% chance of being cost-effective in the EU-licensed population using the current NICE cost-effectiveness threshold of £20,000 per QALY.

Length of publication: 6 pages

Some important notes: Please contact your local NHS library if you cannot access the full text. Follow this link to find your local NHS library.

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

%d bloggers like this: